The global market for Induced Pluripotent Stem Cell (iPSC) is estimated at US$2.0 Billion in 2023 and is projected to reach US$3.2 Billion by 2030, growing at a CAGR of 7.0% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the iPSC market is driven by several factors, including significant advancements in biomedical research and an increasing emphasis on personalized medicine. The potential of iPSCs to provide patient-specific cells for therapy and research has led to substantial investment from both public and private sectors. The expansion of regenerative medicine, seeking to restore or establish normal function by replacing damaged cells, tissues, or organs, heavily relies on innovations in iPSC technology.
Moreover, the growing prevalence of chronic diseases and genetic disorders increases the demand for novel treatment strategies that iPSCs could fulfill. Additionally, regulatory support and ethical acceptance of iPSCs compared to embryonic stem cells encourage further development and application of this technology. These drivers collectively foster a dynamic and rapidly advancing market, promising to revolutionize healthcare and treatment paradigms in the coming years.
The growth in the iPSC market is driven by several factors, including significant advancements in biomedical research and an increasing emphasis on personalized medicine. The potential of iPSCs to provide patient-specific cells for therapy and research has led to substantial investment from both public and private sectors. The expansion of regenerative medicine, seeking to restore or establish normal function by replacing damaged cells, tissues, or organs, heavily relies on innovations in iPSC technology.
Moreover, the growing prevalence of chronic diseases and genetic disorders increases the demand for novel treatment strategies that iPSCs could fulfill. Additionally, regulatory support and ethical acceptance of iPSCs compared to embryonic stem cells encourage further development and application of this technology. These drivers collectively foster a dynamic and rapidly advancing market, promising to revolutionize healthcare and treatment paradigms in the coming years.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Vascular Cells segment, which is expected to reach US$1.1 Billion by 2030 with a CAGR of a 7.5%. The Cardiac Cells segment is also set to grow at 8.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $876.2 Million in 2023, and China, forecasted to grow at an impressive 8.9% CAGR to reach $116.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Induced Pluripotent Stem Cell (iPSC) Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Induced Pluripotent Stem Cell (iPSC) Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Induced Pluripotent Stem Cell (iPSC) Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Lonza Group Ltd., Evotec SE, FUJIFILM Holdings Corporation, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 51 Featured):
- Lonza Group Ltd.
- Evotec SE
- FUJIFILM Holdings Corporation
- Abcam PLC
- Horizon Discovery Ltd.
- Cell Signaling Technology, Inc.
- Cell Applications, Inc.
- Invivogen
- ALSTEM, LLC
- Censo Biotechnologies Ltd.
- Creative Bioarray
- Creative Biolabs
- Axol Bioscience Ltd.
- ID Pharma Co., Ltd.
- BlueRock Therapeutics, LLC
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARYIII. MARKET ANALYSISCANADAITALYREST OF EUROPEREST OF WORLDIV. COMPETITION
1. MARKET OVERVIEW
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
Companies Mentioned
- Lonza Group Ltd.
- Evotec SE
- FUJIFILM Holdings Corporation
- Abcam PLC
- Horizon Discovery Ltd.
- Cell Signaling Technology, Inc.
- Cell Applications, Inc.
- Invivogen
- ALSTEM, LLC
- Censo Biotechnologies Ltd.
- Creative Bioarray
- Creative Biolabs
- Axol Bioscience Ltd.
- ID Pharma Co., Ltd.
- BlueRock Therapeutics, LLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 349 |
| Published | December 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 2 Billion |
| Forecasted Market Value ( USD | $ 3.2 Billion |
| Compound Annual Growth Rate | 7.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
